BSE Live
Mar 27, 16:01Prev. Close
1024.55
Open Price
1019.50
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 27, 15:59Prev. Close
1023.50
Open Price
1019.00
Bid Price (Qty.)
1008.80 (197)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Laurus Labs (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 503.81 | 301.47 | 1,051.43 | 975.41 | 1,274.63 | |
| Net CashFlow From Operating Activities | 540.06 | 658.54 | 881.55 | 822.97 | 694.45 | |
| Net Cash Used In Investing Activities | -591.65 | -756.74 | -735.27 | -836.61 | -899.68 | |
| Net Cash Used From Financing Activities | 59.32 | 139.41 | -185.19 | 15.19 | 243.13 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 7.73 | 41.21 | -38.91 | 1.55 | 37.90 | |
| Cash And Cash Equivalents Begin of Year | 42.63 | 1.42 | 40.33 | 38.78 | 0.88 | |
| Cash And Cash Equivalents End Of Year | 50.36 | 42.63 | 1.42 | 40.33 | 38.78 |
22.03.2026
Sell-on-rise market? SBI Securities sees Nifty under pressure, picks two stocks for the week ahead
20.03.2026
02.03.2026
26.02.2026
27.01.2026
Laurus Labs Consolidated December 2025 Net Sales at Rs 1,778.29 crore, up 25.67% Y-o-Y
27.01.2026
Laurus Labs Standalone December 2025 Net Sales at Rs 1,509.42 crore, up 19.3% Y-o-Y
28.10.2025
Laurus Labs Consolidated September 2025 Net Sales at Rs 1,653.47 crore, up 35.12% Y-o-Y
27.10.2025
Laurus Labs Standalone September 2025 Net Sales at Rs 1,566.60 crore, up 32.22% Y-o-Y
12.04.2021
Laurus Labs Q4 PAT seen up 366.3% YoY to Rs. 232.2 cr: Sharekhan
18.01.2019
Laurus Labs Q3 PAT may dip 48.3% YoY to Rs. 17.8 cr: Sharekhan
17.10.2018
Laurus Labs Q2 PAT may dip 46.7% YoY to Rs. 30 cr: HDFC Securities
17.10.2018
Laurus Labs Q2 PAT may dip 49.4% YoY to Rs. 24.5 cr: Sharekhan
27.03.2026
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
27.03.2026
27.03.2026
26.03.2026
As Strides Pharma stabilises balance sheet, focus shifts to growth beyond the US
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth